The p110αEEE545K/p85α–Cdc42-binding interface may represent a therapeutic target that could inhibit PI3Kα E545K signalling without affecting wild-type PI3Kα signalling in non-tumour cells. The gene discussed is CDC42; the disease is neoplasm.